Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Pharmacokinetics of Multiple Doses of BI 655064 in Healthy Chinese Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 655064
Drug: Placebo

First Posted Date: 2015-01-06

Last Posted Date: 2023-08-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT02331277

Locations: 🇰🇷
1293.9.8201 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of

The Effect of Multiple Doses of BI 187004 on the Single-dose Pharmacokinetics of Repaglinide and Bupropion in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: repaglinide
Drug: BI 187004 tablet
Drug: bupropion extended release tablet

First Posted Date: 2014-12-03

Last Posted Date: 2015-05-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT02305901

Locations: 🇩🇪
1307.20.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Nintedanib
Drug: Docetaxel

First Posted Date: 2014-11-25

Last Posted Date: 2018-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 10

Registration Number: NCT02300298

Locations: 🇯🇵
1199.90.81006 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan
🇯🇵
1199.90.81001 Boehringer Ingelheim Investigational Site, Chiba , Kashiwa, Japan
🇯🇵
1199.90.81003 Boehringer Ingelheim Investigational Site, Kanagawa, Yokohama, Japan

and more 3 locations

Efficacy and Safety of Finalgon® Cream Multiple Doses in Acute Low Back Pain

Phase 3

Completed

Conditions: Low Back Pain

Interventions: Drug: placebo matching nonivamide + nicoboxil (Finalgon cream)
Drug: nonivamide + nicoboxil (Finalgon cream)

First Posted Date: 2014-11-25

Last Posted Date: 2016-09-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 138

Registration Number: NCT02300311

Locations: 🇺🇦
69.53.53202 Boehringer Ingelheim Investigational Site, Kyiv, Ukraine
🇺🇦
69.53.53203 Boehringer Ingelheim Investigational Site, Kyiv, Ukraine
🇷🇺
69.53.53103 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation

and more 5 locations

Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: olodaterol
Drug: tiotropium

First Posted Date: 2014-11-20

Last Posted Date: 2018-06-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 7903

Registration Number: NCT02296138

Locations: 🇺🇸
1237.19.10003 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States
🇺🇸
1237.19.10021 Boehringer Ingelheim Investigational Site, Medford, Oregon, United States
🇨🇦
1237.19.20021 Boehringer Ingelheim Investigational Site, Moncton, New Brunswick, Canada

and more 815 locations

GIOTRIF rPMS in Korean Patients With NSCLC

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: GIOTRIF 20mg
Drug: GIOTRIF 40mg
Drug: GIOTRIF 30mg

First Posted Date: 2014-11-07

Last Posted Date: 2021-02-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1272

Registration Number: NCT02285361

A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: BI 498306 50 mg QD
Drug: BI 409306 10 mg QD
Drug: BI 409306 100 mg QD
Drug: BI 498306 25 mg QD
Drug: Placebo

First Posted Date: 2014-11-04

Last Posted Date: 2017-10-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 518

Registration Number: NCT02281773

Locations: 🇺🇸
Artemis Institute for Clinical Research, LLC, San Diego, California, United States
🇺🇸
Uptown Research Institute, Chicago, Illinois, United States
🇺🇸
Comprehensive Clinical Development, Inc., Cerritos, California, United States

and more 39 locations

Study to Compare the Effect of a Combination of Dipyridamole With Sustained Release and Acetyl Salicylic Acid (Aggrenox®) on the Performance Relevant to Safety and on the General Condition of Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Aggrenox®
Drug: Placebo
Other: Ethanol

First Posted Date: 2014-10-30

Last Posted Date: 2014-10-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 56

Registration Number: NCT02278302

Bioequivalence of Telmisartan as Telmisartan 80 mg/HCTZ 12.5 mg Fixed-dose Combination Tablet or as Two Telmisartan 40 mg Tablets in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Telmisartan
Drug: Telmisartan/HCTZ combination

First Posted Date: 2014-10-28

Last Posted Date: 2014-10-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 64

Registration Number: NCT02276391

Relative Bioavailability of Meloxicam 2 x 7.5 mg Tablets Compared to 15 mg Tablet and Dose Proportionality Over a Dose Range of 7.5 mg and 15 mg in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Treatment 1
Drug: Treatment 2
Drug: Treatment 3

First Posted Date: 2014-10-28

Last Posted Date: 2014-10-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT02276352

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy